Literature DB >> 16111527

Uterine papillary serous carcinoma: what have we learned over the past quarter century?

Barbara A Goff.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16111527     DOI： 10.1016/j.ygyno.2005.07.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  13 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Authors:  Liancheng Zhu; Salvatore Lopez; Stefania Bellone; Jonathan Black; Emiliano Cocco; Tiffany Zigras; Federica Predolini; Elena Bonazzoli; Beatrice Bussi; Zachary Stuhmer; Carlton L Schwab; Diana P English; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Tumour Biol       Date:  2015-02-11

3.  Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.

Authors:  Sarah A Hakim; Nermine M Abd Raboh
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 5.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

6.  Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells.

Authors:  Chun-Jie Gu; Jiao Cheng; Bing Zhang; Shao-Liang Yang; Feng Xie; Jian-Song Sun; Li-Qing Huang; Jin-Jin Yu; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

7.  erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.

Authors:  Karim S Elsahwi; Alessandro D Santin
Journal:  Obstet Gynecol Int       Date:  2011-08-11

8.  Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Authors:  C L Schwab; S Bellone; D P English; D M Roque; S Lopez; E Cocco; R Nicoletti; I Bortolomai; E Bonazzoli; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; A D Santin
Journal:  Br J Cancer       Date:  2014-09-30       Impact factor: 7.640

9.  Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies.

Authors:  Kentaro Nakayama; Naomi Nakayama; Masako Ishikawa; Kohji Miyazaki
Journal:  Cancers (Basel)       Date:  2012-08-07       Impact factor: 6.639

10.  Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment.

Authors:  G R Stodden; M E Lindberg; M L King; M Paquet; J A MacLean; J L Mann; F J DeMayo; J P Lydon; K Hayashi
Journal:  Oncogene       Date:  2014-07-07       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.